Serum osteopontin predicts glycaemic profile improvement in metabolic syndrome: A pilot study
- 11 September 2020
- journal article
- research article
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 51 (3) , e13403
Abstract
Prediabetes is often observed in patients with Metabolic Syndrome (MetS) and might be associated with metabolic and inflammatory alterations. Here, we investigated whether the inflammatory molecule osteopontin (OPN) might have a prognostic impact in a cohort of MetS patients (n = 85) with baseline normal glycaemia or impaired fasting glucose (IFG) over one year of recommended pharmacological treatments and Mediterranean diet. Patients were then followed up for 12 months with intermediate evaluation after 6 months. At all time points, anthropometric and clinical data were recorded, alongside with haematological and biochemical profiles, including serum concentrations of OPN. As expected, Mediterranean diet improves glycaemic profile in patients with IFG. Baseline serum OPN failed to be associated with baseline anthropometric or biochemical variables. At baseline, higher levels of OPN were shown in patients with IFG as compared to normal glycaemia. Two distinct subgroups of patients in whom OPN decreased or remained stable/increased at follow‐up were identified. When higher serum OPN levels were observed at baseline, greater reduction was observed at 1‐year follow‐up. Reduction in circulating OPN levels was associated with metabolic improvement in terms of blood pressure, LDL‐c, HDL‐c, and glycaemia. At both univariate and adjusted logistic regression analyses, serum OPN emerged as an independent predictor of glycaemic profile improvement at 1‐year follow‐up (adjOR 1.05 [1.00‐1.10];P = .041). In conclusion, pharmacological and dietetic interventions improved glycaemic profile in patients with MetS. In particular, glycaemic improvement was demonstrated in patients who also reduce circulating OPN levels. Higher OPN levels at baseline predict normalization of glycaemic profile.Keywords
Funding Information
- Agenzia Italiana del Farmaco, Ministero della Salute (2754291)
- Fondazione Cassa di Risparmio di Genova e Imperia (N/A)
This publication has 44 references indexed in Scilit:
- The inflammatory status score including IL-6, TNF-α, osteopontin, fractalkine, MCP-1 and adiponectin underlies whole-body insulin resistance and hyperglycemia in type 2 diabetes mellitusActa Diabetologica, 2013
- Non‐alcoholic fatty liver disease independently predicts prediabetes during a 7‐year prospective follow‐upLiver International, 2013
- Dysfunctional Adiposity and the Risk of Prediabetes and Type 2 Diabetes in Obese AdultsJAMA, 2012
- Prediabetes: a high-risk state for diabetes developmentThe Lancet, 2012
- Distinct β-Cell Defects in Impaired Fasting Glucose and Impaired Glucose ToleranceDiabetes, 2012
- Plasma Osteopontin Increases After Bariatric Surgery and Correlates with Markers of Bone Turnover But Not with Insulin ResistanceThe Journal of Clinical Endocrinology & Metabolism, 2008
- Plasma Osteopontin Levels and Expression in Adipose Tissue Are Increased in ObesityThe Journal of Clinical Endocrinology & Metabolism, 2007
- PPARα Agonists Suppress Osteopontin Expression in Macrophages and Decrease Plasma Levels in Patients With Type 2 DiabetesDiabetes, 2007
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001
- Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques.Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1994